Susquehanna International Group LLP raised its position in Trinity Biotech PLC (NASDAQ:TRIB) by 37.7% during the third quarter, Holdings Channel reports. The institutional investor owned 43,300 shares of the company’s stock after buying an additional 11,860 shares during the period. Susquehanna International Group LLP owned approximately 0.19% of Trinity Biotech PLC worth $572,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in TRIB. Adage Capital Partners GP L.L.C. acquired a new position in shares of Trinity Biotech PLC during the third quarter worth $1,284,000. Marathon Capital Management raised its position in shares of Trinity Biotech PLC by 12.2% in the third quarter. Marathon Capital Management now owns 121,600 shares of the company’s stock worth $1,608,000 after buying an additional 13,225 shares in the last quarter. Morgan Stanley raised its position in shares of Trinity Biotech PLC by 4.5% in the third quarter. Morgan Stanley now owns 15,345 shares of the company’s stock worth $202,000 after buying an additional 663 shares in the last quarter. Benchmark Capital Advisors raised its position in shares of Trinity Biotech PLC by 6.3% in the third quarter. Benchmark Capital Advisors now owns 96,741 shares of the company’s stock worth $1,279,000 after buying an additional 5,700 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Trinity Biotech PLC during the third quarter worth $170,000. Institutional investors and hedge funds own 70.71% of the company’s stock.

Institutional Ownership by Quarter for Trinity Biotech PLC (NASDAQ:TRIB)

Shares of Trinity Biotech PLC (NASDAQ:TRIB) traded up 2.77% during trading on Friday, hitting $7.04. The stock had a trading volume of 150,570 shares. The company has a market cap of $160.49 million, a PE ratio of 52.93 and a beta of 1.17. The stock has a 50 day moving average of $6.85 and a 200 day moving average of $9.70. Trinity Biotech PLC has a 12 month low of $5.76 and a 12 month high of $13.68.

Trinity Biotech PLC (NASDAQ:TRIB) last announced its quarterly earnings results on Tuesday, October 25th. The company reported $0.07 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.07. The firm earned $26.10 million during the quarter, compared to analyst estimates of $26.50 million. Trinity Biotech PLC had a return on equity of 2.73% and a net margin of 3.04%. Equities analysts forecast that Trinity Biotech PLC will post ($2.54) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first published by Daily Political and is the propert of of Daily Political. If you are viewing this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at http://www.dailypolitical.com/2017/01/13/trinity-biotech-plc-trib-shares-bought-by-susquehanna-international-group-llp.html.

A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded Trinity Biotech PLC from a “sell” rating to a “hold” rating in a research note on Friday, November 11th. Stephens lowered Trinity Biotech PLC from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, October 5th.

Trinity Biotech PLC Company Profile

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

5 Day Chart for NASDAQ:TRIB

Want to see what other hedge funds are holding TRIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trinity Biotech PLC (NASDAQ:TRIB).

Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.